Until the NDA clears in 2027 (best case), the only access route for self-experimenters is the research-peptide market
Fast-acting formulation Designed for quicker response compared to standard formulations
The agents reduce the risk of mortality, myocardial infarction, stroke, reduced kidney function, dementia and cognitive impairment
In contrast, a multicenter retrospective cohort study, including a higher-risk population (23% with CKD) reported slower eGFR decline and lower risks of CKD progression and doubling of serum creatinine among SGLT2 inhibitor users compared with GLP-1 receptor agonist users
To view a copy of this licence, visit About this article Cite this article Kattan, S.W., Almars, A.I., Tounsi, W.A
What remains unknown Despite encouraging data, genuine unknowns exist: Effects beyond 6-9 months of continuous use have not been formally studied in animals or humans